CLPBF:OTC-Coloplast A/S (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC

Last Closing Price

USD 138.92

Change

0.00 (0.00)%

Market Cap

USD 30.65B

Volume

953.00

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catheterization for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. In addition, it provides wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-06 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ESLOY EssilorLuxottica Société ano..

N/A

USD71.32B 40.92 32.10
ESLOF EssilorLuxottica Société ano..

N/A

USD68.61B 40.14 29.91
HOCPY HOYA Corporation

N/A

USD41.45B 43.53 0.23
HOCPF HOYA Corporation

N/A

USD40.68B 44.45 0.23
SDMHF Sartorius Stedim Biotech S.A

N/A

USD35.62B 175.48 69.63
CLPBY Coloplast A/S

N/A

USD30.04B 48.92 5.17
TRUMY Terumo Corporation

N/A

USD28.34B 16.76 0.29
TRUMF Terumo Corporation

N/A

USD28.25B 16.75 0.29
OCPNY Olympus Corporation

N/A

USD28.04B 37.66 0.22
RSMDF ResMed Inc

N/A

USD26.64B 40.38 27.34

ETFs Containing CLPBF

Symbol Name Weight Mer Price(Change) Market Cap
RBIN Nationwide Risk-Based Int.. 0.00 % 0.42 %

N/A

USD0.11B
MVEU:LSE iShares Edge MSCI Europe .. 0.00 % 0.25 %

N/A

USD1.03B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.35% 25% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.35% 25% F 16% F
Trailing 12 Months  
Capital Gain -1.48% 19% F 30% F
Dividend Return 1.50% 57% F 26% F
Total Return 0.03% 19% F 30% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 18.39% 41% F 65% D
Dividend Return 7.15% 100% A+ 86% B
Total Return 25.54% 47% F 68% D+
Risk Return Profile  
Volatility (Standard Deviation) 17.88% 87% B+ 78% C+
Risk Adjusted Return 142.81% 94% A 99% A+
Market Capitalization 30.65B 93% A 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 49.09 32% F 14% F
Price/Book Ratio 35.11 8% F 6% F
Price / Cash Flow Ratio 6.44 39% F 24% F
EV/EBITDA 5.17 55% F 48% F
Management Effectiveness  
Return on Equity 75.59% 98% A+ 99% A+
Return on Invested Capital 55.59% 86% B 91% A-
Return on Assets 26.26% 97% A+ 99% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.08 76% C 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.